Epigral Ltd.
Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins and compounds, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda and potash, chlorine, hydrogen, chloromethanes, captive power plant (CPP), and chlorotoluene value chain, as well as operates wind-solar … Read more
Epigral Ltd. (EPIGRAL) - Net Assets
Latest net assets as of September 2025: ₹21.01 Billion INR
Based on the latest financial reports, Epigral Ltd. (EPIGRAL) has net assets worth ₹21.01 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹32.36 Billion) and total liabilities (₹11.35 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹21.01 Billion |
| % of Total Assets | 64.92% |
| Annual Growth Rate | 24.07% |
| 5-Year Change | 178.39% |
| 10-Year Change | 545.28% |
| Growth Volatility | 17.41 |
Epigral Ltd. - Net Assets Trend (2015–2025)
This chart illustrates how Epigral Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Epigral Ltd. (2015–2025)
The table below shows the annual net assets of Epigral Ltd. from 2015 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹19.05 Billion | +51.86% |
| 2024-03-31 | ₹12.54 Billion | +17.30% |
| 2023-03-31 | ₹10.69 Billion | +47.27% |
| 2022-03-31 | ₹7.26 Billion | +6.12% |
| 2021-03-31 | ₹6.84 Billion | +17.25% |
| 2020-03-31 | ₹5.83 Billion | +18.41% |
| 2019-03-31 | ₹4.93 Billion | -4.75% |
| 2018-03-31 | ₹5.17 Billion | +43.02% |
| 2017-03-31 | ₹3.62 Billion | +22.56% |
| 2016-03-31 | ₹2.95 Billion | +34.01% |
| 2015-03-31 | ₹2.20 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Epigral Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 22055.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹17.85 Billion | 93.72% |
| Common Stock | ₹431.40 Million | 2.27% |
| Other Comprehensive Income | ₹-2.47 Billion | -12.95% |
| Other Components | ₹3.23 Billion | 16.97% |
| Total Equity | ₹19.05 Billion | 100.00% |
Epigral Ltd. Competitors by Market Cap
The table below lists competitors of Epigral Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
A Paradise Acquisition Corp.
NASDAQ:APAD
|
$131.40 Million |
|
Refex Industries Limited
NSE:REFEX
|
$131.41 Million |
|
Acrow Ltd
AU:ACF
|
$131.47 Million |
|
Groupe Guillin SA
PA:ALGIL
|
$131.49 Million |
|
Armada Acquisition Corp. II
NASDAQ:XRPN
|
$131.37 Million |
|
SISB Public Company Limited
BK:SISB
|
$131.32 Million |
|
Appen Limited
PINK:APPEF
|
$131.31 Million |
|
Sermsuk Public Company Limited
BK:SSC
|
$131.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Epigral Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,541,007,000 to 19,045,300,000, a change of 6,504,293,000 (51.9%).
- Net income of 3,576,900,000 contributed positively to equity growth.
- Dividend payments of 418,600,000 reduced retained earnings.
- Share repurchases of 950,000,000 reduced equity.
- Other factors increased equity by 4,295,993,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹3.58 Billion | +18.78% |
| Dividends Paid | ₹418.60 Million | -2.2% |
| Share Repurchases | ₹950.00 Million | -4.99% |
| Other Changes | ₹4.30 Billion | +22.56% |
| Total Change | ₹- | 51.86% |
Book Value vs Market Value Analysis
This analysis compares Epigral Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.89x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 27.42x to 1.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-03-31 | ₹31.12 | ₹853.35 | x |
| 2016-03-31 | ₹41.71 | ₹853.35 | x |
| 2017-03-31 | ₹51.12 | ₹853.35 | x |
| 2018-03-31 | ₹124.51 | ₹853.35 | x |
| 2019-03-31 | ₹118.60 | ₹853.35 | x |
| 2020-03-31 | ₹100.48 | ₹853.35 | x |
| 2021-03-31 | ₹117.09 | ₹853.35 | x |
| 2022-03-31 | ₹174.72 | ₹853.35 | x |
| 2023-03-31 | ₹257.30 | ₹853.35 | x |
| 2024-03-31 | ₹301.83 | ₹853.35 | x |
| 2025-03-31 | ₹450.88 | ₹853.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Epigral Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.78%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.03%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 1.66x
- Recent ROE (18.78%) is below the historical average (23.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 15.75% | 9.86% | 0.66x | 2.43x | ₹126.61 Million |
| 2016 | 22.76% | 16.87% | 0.74x | 1.83x | ₹376.67 Million |
| 2017 | 18.40% | 16.97% | 0.74x | 1.46x | ₹303.68 Million |
| 2018 | 30.05% | 26.04% | 0.89x | 1.30x | ₹1.04 Billion |
| 2019 | 37.10% | 25.74% | 0.68x | 2.12x | ₹1.34 Billion |
| 2020 | 19.20% | 18.36% | 0.48x | 2.18x | ₹536.51 Million |
| 2021 | 14.74% | 12.21% | 0.57x | 2.12x | ₹324.26 Million |
| 2022 | 34.82% | 16.31% | 0.73x | 2.93x | ₹1.80 Billion |
| 2023 | 33.05% | 16.28% | 0.89x | 2.28x | ₹2.46 Billion |
| 2024 | 15.62% | 10.34% | 0.68x | 2.23x | ₹704.56 Million |
| 2025 | 18.78% | 14.03% | 0.81x | 1.66x | ₹1.67 Billion |
Industry Comparison
This section compares Epigral Ltd.'s net assets metrics with peer companies in the Chemicals industry.
Industry Context
- Industry: Chemicals
- Average net assets among peers: $7,566,417,574
- Average return on equity (ROE) among peers: 17.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Epigral Ltd. (EPIGRAL) | ₹21.01 Billion | 15.75% | 0.54x | $131.39 Million |
| Archean Chemical Industries Limited (ACI) | $18.64 Billion | 8.70% | 0.28x | $374.06 Million |
| Amines & Plasticizers Limited (AMNPLST) | $189.73 Million | 16.38% | 2.50x | $10.36 Million |
| The Andhra Sugars Limited (ANDHRSUGAR) | $8.95 Billion | -0.54% | 0.68x | $60.92 Million |
| Bhansali Engineering Polymers Limited (BEPL) | $10.02 Billion | 17.96% | 0.10x | $88.83 Million |
| Chemplast Sanmar Limited (CHEMPLASTS) | $4.98 Billion | 35.86% | 4.35x | $183.76 Million |
| DCW Limited (DCW) | $6.32 Billion | -0.68% | 1.88x | $69.23 Million |
| Deepak Fertilizers and Petrochemicals Corporation Limited (DEEPAKFERT) | $8.10 Billion | 16.91% | 1.17x | $685.82 Million |
| Deepak Nitrite Limited (DEEPAKNTR) | $15.72 Billion | 38.87% | 1.04x | $1.09 Billion |
| DIAMINES AND CHEMICALS ORD (BSE) (DIAMINESQ) | $651.80 Million | 36.80% | 0.17x | $9.53 Million |
| DMCC SPECIALITY CHEMICALS LIMITED (DMCC) | $2.10 Billion | 5.53% | 0.80x | $22.00 Million |